Oncology and Hematology
An oncology CRO, passionate about collaborating for a cure
We are living in a golden age for cancer research and discovery. The ability to have direct impact on tumor cells is increasing at a rapid pace, and patients are living longer thanks to advances in genetics, immunotherapy and precision oncology.
But all this progress only fuels our sense of urgency for the many patients who are still losing their battles with cancer.
By the Numbers
In recent five-year period (2020-2024), helped to develop or commercialize:
96%
novel oncology therapies approved by the FDA
93%
oncology products granted marketing authorization approved by the EMA
Oncology clinical trial experience over the past five years
590
studies
91,000+
patients
23,700+
sites
Meet us at ESMO Congress 2025
Syneos Health will be at ESMO 2025! Schedule a meeting to learn how we can elevate your oncology clinical development.
Enabling your boldest aspirations with experience, insight and scientific innovation
Our therapeutic expertise runs both deep and wide—far beyond the offerings of a traditional CRO. Our oncology clinical trial services extend from preclinical, translational science and clinical development to regulatory and commercialization/marketing capabilities.
We listen closely and then leverage the right combination of experience and insight from across our global organization to offer thoughtful, integrated solutions for achieving your goals.
Syneos Health Oncology Clinical Trials
We bring diverse and measurable experience across the full range of cancer treatment modalities, from immuno-oncology and targeted therapies, to novel and emerging therapies, including cell and gene therapies.
At Syneos Health, we accelerate Early Phase Oncology development—from dose escalation through optimization and expansion—combining global expertise with advanced technologies.
A specialized segment of our Early Phase Oncology expertise includes a refined Dose Escalation Model, generating cost predictability and a better site experience for customers with a smaller dedicated team. This approach helps optimize value and drive impactful engagement.
Our experience with solid tumor clinical trials (including for breast cancer, genitorurinary cancers and non-small cell lung cancer) ranges from antibody-drug conjugates, biomarker-driven therapies to biosimilars and other small molecules. We also have extensive experience conducting radiopharmaceutical and bispecific antibody studies.
Our Immuno-Oncology experts conduct studies of therapies that incite the immune system to combat cancer. Our clinical professionals are currently supporting new approaches to precision medicine in solid tumors (including breast cancer clinical trials) and blood cancers (including multiple myeloma and acute myeloid leukemia clinical trials). We are working with cutting-edge therapies including combination immunotherapies and complex study designs (basket studies, platform trials, umbrella trials, etc.) across all phases of clinical development. We are experienced with conducting trials at the forefront of newer immunotherapy discoveries, including studies of novel immunomodulators and combination treatments.
Cell and gene therapy research poses unique challenges and uncertainties for the investigators and companies pioneering this potentially transformative research, and for the patients and families participating in it.
Having conducted more than 140 cell and gene therapy studies in the past five years (including oncology clinical trials for melanoma and multiple myeloma clinical trials), our holistic yet balanced approach considers multiple aspects of clinical, operational and commercial capabilities to ensure breakthroughs in genetic medicines are achieved.
Our specialists in malignant hematology have worked on some of the most promising novel and emerging therapies in development, in indications ranging from non-Hodgkin’s lymphoma and chronic lymphocytic leukemia to acute myeloid leukemia (AML) and multiple myeloma, transitioning them from early phase to marketing authorization.
In the specialized field of non-malignant hematology, Syneos Health excels in addressing complex trial designs and specific patient population challenges. From congenital and acquired bleeding disorders to various forms of anemia, our expertise encompasses a broad range of conditions, ensuring tailored and effective clinical trial solutions.
We have significant experience and an impressive track record in non-small cell lung cancer clinical trials across cancer therapies:
• Immuno-oncology, including checkpoint inhibitors, monoclonal and bispecific antibodies, vaccines
• Targeted therapies that target specific parts of cancer cells/tumor-specific antigens
• Novel and emerging therapies including antibody-drug conjugates)
Our proven track record meeting the unique challenges of breast cancer clinical studies is made possible by:
- Strong relationships with key investigators, consortia and advocacy groups, built on years of shared expertise and trust
- Advanced AI and tech-enabled strategies to identify, enroll and retain patient populations with specific subtypes or biomarkers, or rare forms of breast cancer
- Operational excellence for timely, quality study delivery through optimized processes
- A patient-centric model that incorporates patient needs and perspectives throughout the clinical trial to ease the burden of participation and improve engagement, adherence and outcomes
Get a detailed look at our capabilities
Why choose Syneos Health for your Oncology-Hematology studies?
We partner with purpose to offer you deep therapeutic expertise, experience in advanced trial design and cutting-edge therapies, strong site relationships, sophisticated, tech-enabled patient recruitment strategies, and operational excellence.
Whether motivated by the personal journey of a cancer patient or the challenge and rigor of cancer clinical research, at Syneos Health, we are passionate about collaborating for a cure.
Engage with Us
Read our perspectives on the latest trends in oncology clinical research.
Check out the Project Optimus Series on the Syneos Health Podcast.
Related Content
Looking for exclusive insight?
